Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4419
Title: | Renal tumours in Australian children: 30 years of incidence, outcome and second primary malignancy data from the Australian Childhood Cancer Registry | Authors: | Jones, B. C. Aitken, J. F. McBride, C. A. O'Callaghan, M. E. Cundy, T. P. Karpelowsky, J. Youlden, D. R. |
Issue Date: | 2020 | Source: | 56, (6), 2020, p. 908-916 | Pages: | 908-916 | Journal: | Journal of Paediatrics and Child Health | Abstract: | Aim: This paper describes the incidence and outcomes of childhood renal malignancies in Australia using national population-based data from the Australian Childhood Cancer Registry. Methods: De-identified data for children (0–14 years) diagnosed with renal malignancies from 1983 to 2015 inclusive were extracted. Cause-specific (CSS) and event-free survival up to 20 years from diagnosis were estimated using the cohort method. Adjusted excess mortality hazard ratios were calculated using a multivariable flexible parametric survival model. Details relating to second primary malignancies (SPMs) were also examined. Results: There were 1046 children diagnosed with renal malignancies in Australia between 1983 and 2015 (91% nephroblastoma), generating an annual age-standardised incidence rate of 8 per million children, which remained constant over the study period. CSS was 89% (95% confidence interval = 87–91%) and 88% (86–90%) at 5 and 20 years, respectively, and 5-year event-free survival was 82% (80–84%). Five-year CSS did not change over the study period and was highest for nephroblastoma (91%). Of the 94% of patients achieving remission, 15% relapsed and subsequent 5-year CSS was 49% (40%–58%). Eleven children were diagnosed with SPM (standardised incidence ratio = 2.9, 95% confidence interval = 1.6–5.3, P < 0.001), and five of them (45%) died within 5 years of the second diagnosis. Conclusions: Children treated for renal malignancies in Australia have excellent long-term survival, which is unchanged since 1983. SPMs are uncommon following treatment for childhood renal cancer but carry a poor prognosis. Relapse carries a similarly poor prognosis to SPM but is more common. These data are comparable to registry outcomes in similarly developed nations.L20040520792020-01-20 | DOI: | 10.1111/jpc.14774 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2004052079&from=exporthttp://dx.doi.org/10.1111/jpc.14774 | | Keywords: | male;mortality risk;newborn;priority journal;second cancer;standardized incidence ratio;nephroblastoma;adolescentarticle;Australian;cancer prognosis;cancer recurrence;cancer registry;cancer regression;cause specific survival;child;cohort analysis;comparative study;developed country;event free survival;female;human;incidence;infant;kidney tumor;long term survival;major clinical study | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.